172 related articles for article (PubMed ID: 20550538)
21. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study.
Budayr A; Tan TC; Lo JC; Zaroff JG; Tabada GH; Yang J; Go AS
BMC Endocr Disord; 2020 Feb; 20(1):25. PubMed ID: 32075620
[TBL] [Abstract][Full Text] [Related]
22. Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints.
Stiles CE; Lloyd G; Bhattacharyya S; Steeds RP; Boomla K; Bestwick JP; Drake WM
J Clin Endocrinol Metab; 2021 Jan; 106(2):e711-e720. PubMed ID: 33247916
[TBL] [Abstract][Full Text] [Related]
23. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies.
Bogazzi F; Manetti L; Raffaelli V; Lombardi M; Rossi G; Martino E
J Endocrinol Invest; 2008 Dec; 31(12):1119-23. PubMed ID: 19246980
[TBL] [Abstract][Full Text] [Related]
24. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
[TBL] [Abstract][Full Text] [Related]
25. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
26. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.
De Vecchis R; Esposito C; Ariano C
Herz; 2013 Dec; 38(8):868-80. PubMed ID: 23743769
[TBL] [Abstract][Full Text] [Related]
27. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Pullan PT
Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
[No Abstract] [Full Text] [Related]
28. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Elenkova A; Shabani R; Kalinov K; Zacharieva S
Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
[TBL] [Abstract][Full Text] [Related]
29. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.
Drake WM; Stiles CE; Howlett TA; Toogood AA; Bevan JS; Steeds RP;
J Clin Endocrinol Metab; 2014 Jan; 99(1):90-6. PubMed ID: 24187407
[TBL] [Abstract][Full Text] [Related]
30. Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.
Levin J; Neudert J; Zwermann L; Näbauer M; Bötzel K
J Neurol; 2011 Nov; 258(11):2097-9. PubMed ID: 21562724
[No Abstract] [Full Text] [Related]
31. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.
Drake WM; Stiles CE; Bevan JS; Karavitaki N; Trainer PJ; Rees DA; Richardson TI; Baldeweg SE; Stojanovic N; Murray RD; Toogood AA; Martin NM; Vaidya B; Han TS; Steeds RP; ; Baldeweg FC; Sheikh UE; Kyriakakis N; Parasuraman SK; Taylor L; Butt N; Anyiam S
J Clin Endocrinol Metab; 2016 Nov; 101(11):4189-4194. PubMed ID: 27571182
[TBL] [Abstract][Full Text] [Related]
32. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study.
Peralta C; Wolf E; Alber H; Seppi K; Müller S; Bösch S; Wenning GK; Pachinger O; Poewe W
Mov Disord; 2006 Aug; 21(8):1109-13. PubMed ID: 16622856
[TBL] [Abstract][Full Text] [Related]
33. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.
Valassi E; Klibanski A; Biller BM
J Clin Endocrinol Metab; 2010 Mar; 95(3):1025-33. PubMed ID: 20130078
[TBL] [Abstract][Full Text] [Related]
34. A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia.
Löndahl M; Nilsson A; Lindgren H; Katzman P
Eur J Endocrinol; 2008 Apr; 158(4):583-5. PubMed ID: 18362307
[TBL] [Abstract][Full Text] [Related]
35. Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly.
Izgi C; Feray H; Cevik C; Saltan Y; Mansuroglu D; Nugent K
J Heart Valve Dis; 2010 Nov; 19(6):797-800. PubMed ID: 21214109
[TBL] [Abstract][Full Text] [Related]
36. [Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease].
Muraki M; Mikami T; Kitaguchi M; Sugawara T; Isonishi K; Kaneko S; Kashiwaba T; Moriwaka F; Yamada S; Onozuka H; Tsutsui H
J Cardiol; 2005 Dec; 46(6):221-7. PubMed ID: 16389741
[TBL] [Abstract][Full Text] [Related]
37. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.
Kars M; Pereira AM; Bax JJ; Romijn JA
Eur J Endocrinol; 2008 Oct; 159(4):363-7. PubMed ID: 18703568
[TBL] [Abstract][Full Text] [Related]
38. Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
Vallette S; Serri K; Serri O
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):49-54. PubMed ID: 20014934
[TBL] [Abstract][Full Text] [Related]
39. Long-term low-dose cabergoline usage: Another association with cardiac valvulopathy.
Tessier S; Lipton BA; Arastu MI; Curiale AM; Longo S; Nanda S
Echocardiography; 2023 Jan; 40(1):61-64. PubMed ID: 36511080
[TBL] [Abstract][Full Text] [Related]
40. [Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline].
Sato T; Kikuchi A; Onoue N; Hiramoto T; Oumi M; Onodera J
Rinsho Shinkeigaku; 2008 Jul; 48(7):486-91. PubMed ID: 18717182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
